# OnCo record nct07544654 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07544654/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07544654", "NCT07544654" ;
  schema:name "DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy"@en ;
  schema:description "A phase 3 trial of Carboplatin and Etoposide in neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07544654/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07544654> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2026-07-10" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/extrapulmonary-nec/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/obrixtamig/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .